prikaz prve stranice dokumenta Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
  Preuzmi
PDF 442.23 KB
Znanstveni rad - Izvorni znanstveni rad
Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
Advances in Therapy, 40 (2023), 6; 2752-2772. https://doi.org/10.1007/s12325-023-02510-4
Bodó, Imre; Amine, Ismail; Boban, Ana; Bumbea, Horia; Kulagin, Alexander; Lukina, Elena; Piekarska, Agnieszka; Preložnik Župan, Irena; Sokol, Juraj; Windyga, Jerzy; Cermak, Jaroslav

Institucijski repozitorij: Dr Med - digitalni repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Citirajte ovaj rad

Bodó, I., Amine, I., Boban, A., Bumbea, H., Kulagin, A., Lukina, E. ... Cermak, J. (2023). Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. Advances in Therapy, 40. (6), 2752-2772. doi: 10.1007/s12325-023-02510-4

Bodó, Imre, et al. "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations." Advances in Therapy, vol. 40, br. 6, 2023, str. 2752-2772. https://doi.org/10.1007/s12325-023-02510-4

Bodó, Imre, Ismail Amine, Ana Boban, Horia Bumbea, Alexander Kulagin, Elena Lukina, Agnieszka Piekarska, et al. "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations." Advances in Therapy 40, br. 6 (2023): 2752-2772. https://doi.org/10.1007/s12325-023-02510-4

Bodó, I., et al. (2023) 'Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations', Advances in Therapy, 40(6), str. 2752-2772. doi: 10.1007/s12325-023-02510-4

Bodó I, Amine I, Boban A, Bumbea H, Kulagin A, Lukina E, i sur.. Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations. Advances in Therapy [Internet]. 04.2023. [pristupljeno 29.12.2024.];40(6):2752-2772. doi: 10.1007/s12325-023-02510-4

I. Bodó, et al., "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations", Advances in Therapy, vol. 40, br. 6, str. 2752-2772, Travanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:527109. [Citirano: 29.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:527109
Podaci o radu
Naslov (engleski)Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations
AutorImre Bodó
AutorIsmail Amine
AutorAna Boban
AutorHoria Bumbea
AutorAlexander Kulagin
AutorElena Lukina
AutorAgnieszka Piekarska
AutorIrena Preložnik Župan
AutorJuraj Sokol
AutorJerzy Windyga
AutorJaroslav Cermak
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Introduction: Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach to manage PNH. Three complement inhibitors are approved by the European Medicines Agency as targeted therapy for PNH: eculizumab and ravulizumab, two humanized monoclonal antibodies targeting the same complement 5 (C5) epitope, approved in 2007 and 2019, respectively, and the more recently approved cyclic peptide, the complement 3 (C3) inhibitor pegcetacoplan. Although national and international PNH treatment guidelines exist, they do not take into consideration the latest clinical trial evidence. Given the lack of evidence-based data for some clinical situations encountered in real life, we identified specific populations of patients who may benefit from switching to proximal C3 from terminal C5 inhibition. Methods: The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, recommendations were prepared and reviewed as part of a Delphi survey to test agreement. Results: Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence. Conclusion: Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient outcomes in Central Europe and worldwide.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaAdvances in Therapy
Brojčani podacivol. 40, br. 6, str. 2752-2772
p-ISSN0741-238X
e-ISSN1865-8652
DOIhttps://doi.org/10.1007/s12325-023-02510-4
URN:NBNurn:nbn:hr:105:527109
Datum objave publikacije2023-04
URL dokumentahttps://link.springer.com/10.1007/s12325-023-02510-4
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2023-11-24 10:43:00